Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Lakshmi Nayak, MD
Study ID
NCT04906096
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Non-Hodgkin Lymphoma of Extranodal Site
  • Primary Central Nervous System Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PAXALISIB — DRUG
    Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol

Study Details

This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)

Key Dates

Start date
Jun 1, 2021
Status verified
Jun 2025
Primary completion
Dec 1, 2026
Completion
Dec 1, 2027

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PAXALISIB
    The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits. * Paxalisib (GDC-0084) * Each study treatment cycle lasts 28 days, up to 24 months.

Primary Outcome Measure

Number of participants with Objective Response Rate (ORR) [ Time Frame: Up to 24 Months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02115
Lakshmi Nayak, MD
Lakshmi Nayak, MD (PRINCIPAL_INVESTIGATOR)
Dana Farber Cancer InstituteBostonMassachusetts02115
Lakshmi Nayak, MD
[email protected]
(617) 632-2166

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MADana Farber Cancer Institute· Boston, MA

Related Studies